Erin Choi
Research Subjects
Research Interests
Erin Choi has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
Asher George
1 shared publicationJaime Camacho
Department of Urology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
1 shared publicationJohn D Buie
Department of Urology, School of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, USA
1 shared publicationMhd Hasan Almekdash
1 shared publicationPranav Sharma
1 shared publication- Pranav Sharma
Department of Urology, Texas Tech University Health Sciences Center, Lubbock, TX, USA
1 shared publication
Latest Publications
- Open Access
- 22 July 2022
- Published by Texas Tech University Health Sciences Center Department of Internal Medicine in The Southwest Respiratory and Critical Care Chronicles
- Vol. 10 (44) , 15-21
Frailty is an independent predictor of 90-day complications following robot-assisted radical prostatectomy
Objective: The aim of this study is to analyze the association between the 11-item Modified Frailty Index (mFI) and 90-day post-operative complications in prostate cancer patients undergoing Robot-assisted Radical Prostatectomy (RARP). Methods: mFI was measured for 216 men who underwent RARP at a single institution. Mean ranks and proportions were compared with the Kruskal-Wallis test, Chi-square test of independence, and Fisher's exact test. Multivariate logistic regression was performed to determine predictors of 90-day post-operative complications after RARP. Results: Patients with higher pre-operative mFI (≥2) were more likely to be older in age (P= 0.047), have worse ECOG performance status (P=0.018), and worse ASA scores (P<0.01). Intra-operative variables and pathological characteristics were similar between mFI groups. Multivariate logistic regression showed that mFI ≥2 was a predictor of overall 90-day complications after surgery (OR=3.32, CI=1.16-9.54, P=0.026). Multivariate logistic regression also showed that mFI ≥2 was a predictor of high-grade 90-day complications after surgery (OR=2.69, CI=1.24-5.85, P=0.012). Conclusion: Prostate cancer patients with higher pre-operative mFI scores were more likely to have a 90-day complication after RARP. mFI should be assessed pre-operatively for prostate cancer patients to determine the risk of post-operative morbidity and the best treatment plan.
- 22 July 2022
- Published by Texas Tech University Health Sciences Center Department of Internal Medicine in The Southwest Respiratory and Critical Care Chronicles
- Vol. 10 (44) , 15-21
Open AccessFrailty is an independent predictor of 90-day complications following robot-assisted radical prostatectomy
Objective: The aim of this study is to analyze the association between the 11-item Modified Frailty Index (mFI) and 90-day post-operative complications in prostate cancer patients undergoing Robot-assisted Radical Prostatectomy (RARP). Methods: mFI was measured for 216 men who underwent RARP at a single institution. Mean ranks and proportions were compared with the Kruskal-Wallis test, Chi-square test of independence, and Fisher's exact test. Multivariate logistic regression was performed to determine predictors of 90-day post-operative complications after RARP. Results: Patients with higher pre-operative mFI (≥2) were more likely to be older in age (P= 0.047), have worse ECOG performance status (P=0.018), and worse ASA scores (P<0.01). Intra-operative variables and pathological characteristics were similar between mFI groups. Multivariate logistic regression showed that mFI ≥2 was a predictor of overall 90-day complications after surgery (OR=3.32, CI=1.16-9.54, P=0.026). Multivariate logistic regression also showed that mFI ≥2 was a predictor of high-grade 90-day complications after surgery (OR=2.69, CI=1.24-5.85, P=0.012). Conclusion: Prostate cancer patients with higher pre-operative mFI scores were more likely to have a 90-day complication after RARP. mFI should be assessed pre-operatively for prostate cancer patients to determine the risk of post-operative morbidity and the best treatment plan.
- Open Access
- 1 March 2022
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 14, 87-108
Evolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers
Androgen deprivation therapy (ADT) has been the main management strategy for prostate cancer for more than eight decades, nowadays achieved commonly by administration of luteinizing hormone-releasing hormone agonists. ADT markedly suppresses androgen hormones with the long-term risks of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and secondary fractures. Extensive research has provided significantly better insight into the dynamics of ADT including identification of the benefits of sequential and combination therapies. This has led to the development of new pharmaceutical ADT modalities. This review provides a general overview of the evolution of ADT in the context of the new emerging pharmaceutical ADT modalities so that clinicians and medical providers have a better understanding of personalizing the available ADT options with their different risk-benefit profiles.
- 1 March 2022
- Published by Taylor & Francis in Research and Reports in Urology
- Vol. ume 14, 87-108
Open AccessEvolution of Androgen Deprivation Therapy (ADT) and Its New Emerging Modalities in Prostate Cancer: An Update for Practicing Urologists, Clinicians and Medical Providers
Androgen deprivation therapy (ADT) has been the main management strategy for prostate cancer for more than eight decades, nowadays achieved commonly by administration of luteinizing hormone-releasing hormone agonists. ADT markedly suppresses androgen hormones with the long-term risks of adverse events such as muscle weakness, impairment of glucose and lipid metabolism, impotence, osteoporosis, and secondary fractures. Extensive research has provided significantly better insight into the dynamics of ADT including identification of the benefits of sequential and combination therapies. This has led to the development of new pharmaceutical ADT modalities. This review provides a general overview of the evolution of ADT in the context of the new emerging pharmaceutical ADT modalities so that clinicians and medical providers have a better understanding of personalizing the available ADT options with their different risk-benefit profiles.